Hidetoshi Hayashi

Hidetoshi Hayashi

Sakai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 382 publications

Bidirectional Regulation of c-Myc and TRB1 Establishes Oncogenic Reciprocal Regulation.

Bidirectional Regulation of c-Myc and TRB1 Establishes Oncogenic Reciprocal Regulation.

Journal: Biological & pharmaceutical bulletin

Published: August 30, 2026

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Journal: Targeted oncology

Published: June 30, 2026

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Journal: Future oncology (London, England)

Published: April 15, 2026

Effectiveness and Implementation of Physical Activity Interventions for Rural Breast Cancer Survivors: A Systematic Review.

Effectiveness and Implementation of Physical Activity Interventions for Rural Breast Cancer Survivors: A Systematic Review.

Journal: Cureus

Published: March 30, 2026

Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer.

Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer.

Journal: International journal of clinical oncology

Published: March 13, 2026

Association Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Antivascular Endothelial Growth Factor-Related Proteinuria in Solid Tumors: A Systematic Review and Meta-Analysis.

Association Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Antivascular Endothelial Growth Factor-Related Proteinuria in Solid Tumors: A Systematic Review and Meta-Analysis.

Journal: Cureus

Published: March 11, 2026

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 26, 2026

Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].

Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 23, 2026

Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.

Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.

Journal: Med (New York, N.Y.)

Published: February 21, 2026

Efficacy and Safety of Human Epidermal Growth Factor Receptor 2 (HER2) Antibody-Drug Conjugates in Solid Tumors Harboring Non-tyrosine Kinase Domain ERBB2 Mutations: A Systematic Review.

Efficacy and Safety of Human Epidermal Growth Factor Receptor 2 (HER2) Antibody-Drug Conjugates in Solid Tumors Harboring Non-tyrosine Kinase Domain ERBB2 Mutations: A Systematic Review.

Journal: Cureus

Published: February 11, 2026

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.

Journal: International journal of clinical oncology

Published: February 04, 2026

Showing 1-12 of 382

Last Updated: 09/26/2026